Skip to main content
Log in

Futibatinib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Futibatinib (Lytgobi®) is an oral, covalently binding, irreversible inhibitor of fibroblast growth factor receptor (FGFR)1–4 that is being developed by Taiho Oncology and Taiho Pharmaceutical for the treatment of cancers, including cholangiocarcinoma, breast cancer, gastric cancer, urothelial cancer, oesophageal cancer and non-small cell lung cancer. Futibatinib was approved in the USA on 30 September 2022 for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring FGFR2 gene fusions or other rearrangements. This article summarizes the milestones in the development of futibatinib leading to this first approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haugsten EM, Wiedlocha A, Olsnes S, et al. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010;8(11):1439–52.

    Article  CAS  Google Scholar 

  2. Helsten T, Elkin S, Arthur E, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–67.

    Article  CAS  Google Scholar 

  3. Krook MA, Reeser JW, Ernst G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124(5):880–92.

    Article  CAS  Google Scholar 

  4. Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31(10):1405–12.

    Article  CAS  Google Scholar 

  5. Taiho Oncology. LYTGOBI® (futibatinib) tablets, for oral use: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Accessed 21 Oct 2022.

  6. European Medicines Agency. Medicines for human use under evaluation. 2022. https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation. Accessed 21 Oct 2022.

  7. Taiho Pharmaceutical Co. Taiho Pharmaceutical submits new drug application of FGFR inhibitor futibatinib (TAS-120) for biliary tract cancer [media release]. 28 Jul 2022. http://www.taiho.co.jp.

  8. National Comprehensive Cancer Network. NCCN Oncology Research Program to oversee trials of the FGFR inhibitor futibatinib in tumors with aberrant FGFR expression, in collaboration with Taiho Oncology [media release]. 27 Jan 2020. http://www.nccn.org.

  9. National Comprehensive Cancer Network. NCCN Oncology Research Program announces projects selected for funding to study futibatinib in tumors with aberrant FGFR expression, in collaboration with Taiho Oncology [media release]. 23 Jul 2020. http://www.nccn.org.

  10. Sootome H, Fujita H, Ito K, et al. Futibatinib Is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986–97.

    Article  CAS  Google Scholar 

  11. Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494–500.

    Article  CAS  Google Scholar 

  12. Sootome H, Miura A, Komori T, et al. Futibatinib (TAS-120) plus chemotherapy demonstrates a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models [abstract no. 564]. Cancer Res. 2020;80(Suppl 16).

  13. Miura A, Sootome H, Komori T, et al. Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors [abstract no. 659]. Cancer Res. 2020;80(Suppl 16).

  14. Iwasaki J, Kuramoto T, Komori T. Synergistic antitumor activity of futibatinib, an FGFR1-4 inhibitor, and TAS-117, a selective AKT inhibitor, in FGFR-deregulated cancer models [abstract no. 661]. Cancer Res. 2020;80(Suppl 16).

  15. Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–79.

    Article  CAS  Google Scholar 

  16. Cleary JM, Raghavan S, Wu Q, et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 2021;11(10):2488–505.

    Article  CAS  Google Scholar 

  17. Hollebecque A, Bridgewater JA, Meric-Bernstam F, et al. Assessment of futibatinib exposure-response (E-R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA) [abstract no. 52P]. Ann Oncol. 2021;32(Suppl 5):S378.

    Article  Google Scholar 

  18. Morizane C, Kojima T, Kuboki Y, et al. Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours [abstract no. 544P]. Ann Oncol. 2020;31(Suppl 4):S475.

    Article  Google Scholar 

  19. Goyal L, Meric-Bernstam F, Hollebecque A, et al. Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements [abstract no. CT010]. Cancer Res. 2021;81(Suppl 13).

  20. Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/ rearrangements [abstract no. 4009]. J Clin Oncol. 2022;40(Suppl 16).

  21. Valle JW, Hollebecque A, Furuse J, et al. FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements [abstract no. 4097]. J Clin Oncol. 2021;39(Suppl 15).

  22. Borad MJ, Paine A, Wacheck V, et al. Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements [abstract no. 440]. J Clin Oncol. 2022;40(Suppl 4).

  23. Meric-Bernstam F, Bahleda R, Hierro C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 2022;12(2):402–15.

    Article  CAS  Google Scholar 

  24. Kuboki Y, Shitara K, Morizane C, et al. Phase I study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: updated dose expansion results and activity in gastric cancer [abstract no. 1383P]. Ann Oncol. 2021;32(Suppl 5):S1047–8.

    Article  Google Scholar 

  25. Muro K, Kato K, Chin K, et al. Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: tolerability results and antitumor activity in esophageal carcinoma [abstract no. 1241P]. Ann Oncol. 2022;33(Suppl 7):S1116.

    Article  Google Scholar 

  26. Damodaran S, Unni N, Giridhar KV, et al. Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: preliminary data from a phase 2 study [abstract no. P1-18-35]. Cancer Res. 2022;82(Suppl 4).

  27. Koshkin VS, Sonpavde GP, Hwang C, et al. Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): preliminary safety results from a phase 2 study [abstract no. 501]. J Clin Oncol. 2022;40(Suppl 6).

  28. Meric-Bernstam F, Furuse J, Oh D, et al. Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA) [abstract no. 51P]. Ann Oncol. 2021;32(Suppl 5):S378.

    Article  Google Scholar 

  29. Taiho Oncology. FDA approves Taiho's LYTGOBI® (futibatinib) tablets for previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma [media release]. 30 Sep 2022 2022. http://www.taihooncology.com.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yahiya Y. Syed.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 501 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Syed, Y.Y. Futibatinib: First Approval. Drugs 82, 1737–1743 (2022). https://doi.org/10.1007/s40265-022-01806-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-022-01806-z

Navigation